Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

DEPICT-1 Investigators

Research output: Contribution to journalArticlepeer-review

148 Scopus citations

Fingerprint Dive into the research topics of 'Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences